Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2007-09-25
2007-09-25
Kim, Vickie (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S674000, C514S654000
Reexamination Certificate
active
10286604
ABSTRACT:
The present invention provides methods and compositions for modulating polyamine pathway activity as a means for ameliorating neurodegenarative disorders. In particular, for ameliorating the symptoms or onset of amyotrophic lateral sclerosis (ALS) by modulating the gene and protein products involved the polyamine pathway, such as by inhibiting the enzyme, ornithine decarboxylase (ODC), involved in the synthesis of the polyamine, putrescine. Compositions and methods are disclosed for inhibiting the polyamine pathway producing lower polyamine levels resulting in a beneficial effect on ALS. This can be accomplished by using modulating agents such as analogs, or polyamine analogs, and antiproliferative drugs. In particular, the ODC inhibitor difuoromethylornithine (DFMO) is disclosed as a useful pharmacological agent in the modulation and treatment of ALS. Screening assays for pharmacological agents that are capable of decreasing polyamine levels and/or reducing cell proliferation are also disclosed.
REFERENCES:
patent: 4499072 (1985-02-01), Sunkara et al.
patent: 5541230 (1996-07-01), Basu et al.
patent: 5637768 (1997-06-01), Jund et al.
patent: 5646188 (1997-07-01), Gilad et al.
patent: 5670477 (1997-09-01), Poduslo et al.
patent: 5677349 (1997-10-01), Gilad et al.
patent: 5770625 (1998-06-01), Nakanishi et al.
patent: 5851537 (1998-12-01), Alberts et al.
patent: 5880161 (1999-03-01), Basu et al.
patent: 5886051 (1999-03-01), Bergeron, Jr. et al.
patent: 5906996 (1999-05-01), Murphy
patent: 5962533 (1999-10-01), Bergeron, Jr.
patent: 6020139 (2000-02-01), Schwartz et al.
patent: 6166079 (2000-12-01), Follen et al.
patent: 6172261 (2001-01-01), Vermeulin et al.
patent: 6184232 (2001-02-01), Bergeron, Jr.
patent: 6194000 (2001-02-01), Smith et al.
patent: 6235794 (2001-05-01), Bergeron, Jr.
patent: 6277411 (2001-08-01), Shaked et al.
patent: 6342534 (2002-01-01), Bergeron, Jr.
patent: 6392098 (2002-05-01), Frydman et al.
patent: 6423754 (2002-07-01), Holmes-Farley et al.
patent: 6576672 (2003-06-01), Murphy
patent: 6596701 (2003-07-01), Schwartz et al.
patent: 6653351 (2003-11-01), Levin
patent: 6949679 (2005-09-01), Poulin et al.
patent: 7030126 (2006-04-01), Ramesh et al.
patent: 2002/0137797 (2002-09-01), Meyskens et al.
patent: 2003/0013772 (2003-01-01), Murphy et al.
patent: 2003/0130350 (2003-07-01), Ramesh et al.
patent: 0 434 173 (1989-12-01), None
patent: 0 361 687 (1990-04-01), None
patent: 0 436 332 (1991-07-01), None
patent: 0436 332 (1991-07-01), None
patent: 0 950 406 (1999-10-01), None
patent: 0 950 406 (1999-11-01), None
patent: 07024965 (1996-08-01), None
patent: 10-087506 (1998-04-01), None
patent: WO98/25603 (1998-06-01), None
patent: WO99/08519 (1999-02-01), None
patent: WO99/21542 (1999-05-01), None
patent: WO99/65516 (1999-12-01), None
patent: WO 00/66587 (2000-11-01), None
patent: WO01/68076 (2001-09-01), None
patent: WO 01/85981 (2001-11-01), None
patent: WO 01/85981 (2001-11-01), None
patent: WO 02/053519 (2002-07-01), None
Mayo clinic, In an Animal Study, Mayo Clinic Researchers identify . . . , (Abstract only), Dec. 19, 2000.
Gonzalez Deniselle, Maria Claudia et al, “Glucocorticoid Receptors And Actions In The Spinal Cord of the Wobbler Mouse, a Model for Neurodegenerative Diseases”, J. Steroid Biochem. Molec. Biol., vol. 60, No. 3-4, pp. 205-213 (1997).
Scorcioni, Francesca et al. “Manipulation of the Expression of Regulatory Genes of Polyamine Metabolism Results in Specific Alterations of the Cell-Cycle Progression” Biochem. J. Vol. 354, pp. 217-223 (2001).
Thomas T. and Thomas T.J., “Polyamines in Cell Growth and Cell Death: Molecular Mechanisms and Therapeutic Applications”, CMLS, Cell. Mol. Life Sci., vol. 58, pp. 244-258 (2001).
Ramesh Tennore
Scott Sean
ALS Therapy Development Foundation, Inc.
Engellenner Thomas J.
Kim Vickie
Miller Deborah A.
Nutter & McClennen & Fish LLP
LandOfFree
Use of difluoromethylornithine (DFMO) for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of difluoromethylornithine (DFMO) for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of difluoromethylornithine (DFMO) for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3773628